Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to $8.3 million.

  • Tarsus Pharmaceuticals' Cost of Revenue rose 15629.24% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year increase of 17076.57%. This contributed to the annual value of $12.8 million for FY2024, which is 70514.75% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Cost of Revenue stood at $8.3 million, which was up 15629.24% from $6.2 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Cost of Revenue high stood at $8.3 million for Q3 2025, and its period low was -$24000.0 during Q4 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Cost of Revenue had a median value of $1.3 million in 2021 and averaged $2.3 million.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Cost of Revenue in the last 5 years was 176666.67% (2022), contrasted with its biggest fall of 9745.57% (2022).
  • Over the past 5 years, Tarsus Pharmaceuticals' Cost of Revenue (Quarter) stood at -$24000.0 in 2021, then surged by 1766.67% to $400000.0 in 2022, then skyrocketed by 204.0% to $1.2 million in 2023, then skyrocketed by 305.1% to $4.9 million in 2024, then surged by 68.68% to $8.3 million in 2025.
  • Its Cost of Revenue was $8.3 million in Q3 2025, compared to $6.2 million in Q2 2025 and $5.2 million in Q1 2025.